Literature DB >> 27022069

Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients.

Ann M Moyer1, Amy K Saenger2, Maria Willrich1, Leslie J Donato1, Nikola A Baumann1, Darci R Block1, Chad M Botz1, Munawwar A Khan3, Allan S Jaffe1, Curtis A Hanson1, Brad S Karon4.   

Abstract

BACKGROUND: We assessed the impact of clinical decision support (CDS) rules within the electronic health record for ionized calcium (iCa), serum magnesium (Mg), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in intensive care unit (ICU) inpatients at a large academic center.
METHODS: A repeat order for measurement of iCa or Mg placed within 24 (iCa) or 48 (Mg) h of a previously nonactionable result, or additional orders for NT-proBNP beyond 1 within a single hospitalization, triggered a CDS pop-up alert showing the prior result and offering the opportunity to cancel the order or to place the order after entering an indication for repeat testing. The number of tests performed for each of these analytes and incidence of adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia were compared between the 90-day period before CDS implementation and two 90-day periods immediately following.
RESULTS: iCa test volumes decreased by 48%, Mg by 39%, and NT-proBNP by 28% in the 90-day period immediately following implementation and remained decreased by 54%, 49%, and 22%, respectively, during the following 90-day period (all P values <0.0002). Adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia did not increase (all P-values >0.17).
CONCLUSIONS: Implementation of CDS dramatically decreased repeat testing of iCa, Mg, and NT-proBNP without adversely impacting clinical outcomes in the ICU. Expansion of the rules from the ICU units to include the entire hospitalized patient population and expansion to additional analytes is expected to lead to further reductions in testing.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27022069     DOI: 10.1373/clinchem.2015.250514

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

Review 1.  Enhancing the Clinical Value of Medical Laboratory Testing.

Authors:  Kenneth A Sikaris
Journal:  Clin Biochem Rev       Date:  2017-11

2.  Impact of nonintrusive clinical decision support systems on laboratory test utilization in a large academic centre.

Authors:  Kevin P Eaton; Natasha Chida; Ariella Apfel; Leonard Feldman; Adena Greenbaum; Susan Tuddenham; Emily A Kendall; Amit Pahwa
Journal:  J Eval Clin Pract       Date:  2018-02-15       Impact factor: 2.431

3.  Analysis of Daily Laboratory Orders at a Large Urban Academic Center: A Multifaceted Approach to Changing Test Ordering Patterns.

Authors:  Joseph W Rudolf; Anand S Dighe; Christopher M Coley; Irina K Kamis; Bradley M Wertheim; Douglas E Wright; Kent B Lewandrowski; Jason M Baron
Journal:  Am J Clin Pathol       Date:  2017-08-01       Impact factor: 2.493

Review 4.  Reducing Test Utilization in Hospital Settings: A Narrative Review.

Authors:  Renuka S Bindraban; Maarten J Ten Berg; Christiana A Naaktgeboren; Mark H H Kramer; Wouter W Van Solinge; Prabath W B Nanayakkara
Journal:  Ann Lab Med       Date:  2018-09       Impact factor: 3.464

5.  Improving laboratory test utilisation at the multihospital Yale New Haven Health System.

Authors:  Roa Harb; David Hajdasz; Marie L Landry; L Scott Sussman
Journal:  BMJ Open Qual       Date:  2019-09-18

Review 6.  Laboratory Demand Management Strategies-An Overview.

Authors:  Cornelia Mrazek; Elisabeth Haschke-Becher; Thomas K Felder; Martin H Keppel; Hannes Oberkofler; Janne Cadamuro
Journal:  Diagnostics (Basel)       Date:  2021-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.